Harnessing synthetic biology for phage therapy and probiotic development

Technology Networks feature by Blake Forman on how synthetic biology is used to modify antibiotics, improve antibiotic production and engineer more targeted phages, including CRISPR–Cas-armed phages, alongside engineered probiotics and biosensors. It describes SNIPR Biome’s SNIPR001, a combination of the four most complementary CRISPR–Cas-armed phages targeting E. coli, which has entered clinical development.